Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial.

Name: Αlpha¹ Rigor Record — Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial.
Item: Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial.
Rating: 96
Author: Αlpha¹

Ortiz JR, Kurup D, Kaufman AC, Ben Hamed S, LaRocco AM, Lyke KE, Litts SM, Datta S, Liang Y, McGilvray MF, Losignor JA, Oshinsky JJ, Palmer KV, Johnson-Mayo IP, Scher G, Balakumar U, Chandwani A, Rapaka RR, Deming ME, Chua JV, Wirblich C, Chen WH, Neuzil KM, Pasetti MF, Schnell MJ

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 2 high issues for “Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 1 clinical trial is methodologically rigorous with clear randomization, blinding, and detailed reporting of demographics and ethics. The main weakness is the vague data availability statement, which lacks a specific repository or accession number, and minor reporting gaps such as not explicitly citing a reporting guideline and occasional threshold-only p-values.

Both reviewers classified the study as interventional and agreed on all dimension statuses. The only divergence was in key resources (software identification) and statistical analysis (exact p-values), resolved by adopting the more specific evidence from Reviewer 2. The statistics verification recomputed only 2 tests; the rest are unverified. The citation check found no retracted or unresolved references.

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction thoroughly reviews the epidemiology of Lassa fever, the lack of licensed vaccines, and the immune mechanisms of protection, citing numerous references. It also describes the development of LASSARAB and its preclinical efficacy in animal models, providing a logical rationale for the trial. Limitations of prior research are implicitly addressed by noting the absence of immune correlates and the need for clinical evaluation.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on Lassa fever burden, vaccine development challenges, and preclinical data supporting LASSARAB.

Evidence

direct quote[Introduction, first paragraph]

“Lassa fever causes substantial morbidity and mortality in West Africa, and no licensed vaccine is available.”